QPPV.COM KNOWLEDGE ASSESSMENT

EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls

Test your understanding of the concepts covered by EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which change is specifically relevant to pharmacovigilance system change control under the article's discussion of GVP Module II?

A change to office furniture unrelated to pharmacovigilance activities A safety-database migration or significant outsourced-service change A routine marketing campaign with no safety-system impact A change in a product's packaging artwork with no associated process impact

Question 2 of 10 Which situation most clearly illustrates a gap between contractual and operational transition?

A new vendor begins work after readiness testing and documented handover The incoming vendor is formally appointed, but the outgoing vendor reduces support before the incoming provider demonstrates operational capability A service agreement is amended before the agreed operational start date Both vendors maintain documented responsibilities during a controlled overlap

Question 3 of 10 Which sequence best represents a controlled lifecycle-transition approach?

Legal completion, document filing, project closure, retrospective impact assessment Impact assessment, transition design, implementation, verification and stable-state oversight System cutover, staff training, legal approval, contract negotiation and monitoring PSMF revision, portfolio transfer, inspection response and then responsibility allocation

Question 4 of 10 Which approach is most appropriate for post-transition verification?

Close the project once the planned cutover has occurred Use risk-based checks such as case sampling, reconciliation review, workflow testing, access confirmation and commitment review Repeat every historical process in full regardless of transition complexity Rely solely on personnel training-completion percentages

Question 5 of 10 A serious case is received shortly before an MA transfer, followed up afterward and reported under the transferee's arrangements. What would provide the strongest evidence of continuity?

A statement from the project manager that the transfer was successful The final case record alone, without its history Contemporaneous records showing responsibility, handover, processing and reporting across the transition boundary A revised PSMF issued several months after the transfer

Question 6 of 10 A company transfers a portfolio but does not inventory ongoing signals, studies and regulatory commitments. What weakness does this most directly indicate?

A failure to distinguish legal ownership from pharmacovigilance consequences An excessive focus on post-transition monitoring A requirement to replace all existing vendors A problem limited to product labelling

Question 7 of 10 What should a safety-database migration assessment emphasize beyond technical functionality?

Only whether users can log in to the new database Data integrity, reconciliation, access controls, deviation management and continued usability of historical information Whether the new database has the same visual design as the old one Whether all legacy users are given permanent access to both systems

Question 8 of 10 Which evidence package would best support an inspection of a complex acquisition involving multiple safety databases and vendors?

A single project closure memo Only the revised PSMF and final organisational chart Connected evidence including impact assessment, responsibility mapping, migration testing, contracts, training, handover, deviations and post-transition monitoring A list of employees who attended the acquisition announcement

Question 9 of 10 Which finding pattern is best described as an incomplete impact assessment?

The organisation assessed only the commercial or legal event and did not evaluate affected products, activities, systems, vendors or records The organisation performed risk-based post-transition monitoring The organisation documented a justified difference between the plan and implementation The organisation preserved historical records and tested their retrieval

Question 10 of 10 Which statement best captures the relationship between lifecycle management and CAPA effectiveness?

Correcting one affected case always demonstrates effective CAPA CAPA should address the transition mechanism and test whether the relevant preventive control works across potentially affected scope CAPA is unnecessary if the transition project was formally closed Effectiveness verification should assess only whether an action-list item was marked complete

EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls

Cookie Settings